News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • RadNet Q2 revenue hit $622.7 million, up 25% year-over-year.
  • RadNet adjusted EBITDA rose to $99.7 million, up 22.7%.
  • Digital Health revenue surged 56.5%, driving RadNet segment growth.
  • RadNet raised 2026 Imaging Center guidance and reaffirmed Digital Health outlook.
  • Moscow exchange closed flat while 220 stocks advanced and 22 declined.
  • Rouble strengthened, gold jumped, and miners plus utilities led market gains.

Latest Articles

Raymond James Sees Value in Canadian Energy Names After Stocks Trail Oil

Raymond James Sees Value in Canadian Energy Names After Stocks Trail Oil

Raymond James found that most Canadian energy stocks lagged the WTI commodity strip and the TSX between Feb. 27 and Apr. 17, with nearly 60% of names posting negative total returns. The firm says exploration and integrated companies are trading at double-digit sustaining free cash flow yields at $70 WTI and continues to favor a basket of large-cap …

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Pharvaris announced presentation of clinical data supporting the safety of combined use of deucrictibant immediate-release capsules and extended-release tablets for prophylactic and on-demand treatment of bradykinin-mediated angioedema, including hereditary angioedema (HAE). The data suggest adequate safety margins and potential efficacy for this c…

Psychedelic drug developers jump after Trump orders faster FDA reviews

Psychedelic drug developers jump after Trump orders faster FDA reviews

Shares of companies developing psychedelic therapies climbed in premarket trading after President Donald Trump signed an executive order directing federal health regulators to expedite reviews of psychedelic treatments and to increase federal research funding for ibogaine. The order could significantly shorten FDA review timelines for qualifying dr…

Strait Tensions Return as Markets Weigh Stop-Start Ceasefire

Strait Tensions Return as Markets Weigh Stop-Start Ceasefire

Markets opened the week with renewed uncertainty after Iran reversed course over the weekend and again restricted passage through the Strait of Hormuz, following a brief reopening on Friday. The episode, in which Iranian forces fired on tankers and the United States seized an Iranian cargo ship, left traders questioning what, if anything, had been …

B2Gold Announces Agreement to Sell its 70% Interest in Fingold Joint Venture to Agnico Eagle for US$325 million; B2Gold and Agnico Eagle to Enter into Nunavut Collaboration Agreement

B2Gold Announces Agreement to Sell its 70% Interest in Fingold Joint Venture to Agnico Eagle for US$325 million; B2Gold and Agnico Eagle to Enter into Nunavut Collaboration Agreement

B2Gold Corp. announced the sale of its 70% interest in the Fingold Ventures Ltd. joint venture to Agnico Eagle Mines Limited for US$325 million in cash. Alongside this transaction, the companies have agreed to collaborate on gold mining operations in Nunavut, Canada, aiming to share expertise and improve operational efficiencies in arctic environme…

BDX: Reasonable Value Today, But Not a Free Lunch

BDX: Reasonable Value Today, But Not a Free Lunch

Becton, Dickinson (BDX) looks comfortably priced against its cash flow and dividend pedigree, but the market is still demanding proof of a durable earnings re-acceleration. This trade plan buys into recurring consumables revenue and FCF strength while protecting capital with a tight stop and a near-term target tied to mean reversion toward prior re…

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

Silo Pharma highlights its lead program, SPC-15, an intranasal serotonin 4 receptor agonist targeting prophylactic treatment of PTSD, coinciding with President Trump's executive order accelerating psychedelic therapy research. SPC-15 benefits from rapid nose-to-brain delivery and a streamlined regulatory pathway, positioning the company to leverage…

UBS: CTAs May Substantially Boost S&P 500 Futures Exposure by End of April

UBS: CTAs May Substantially Boost S&P 500 Futures Exposure by End of April

UBS analyst Nicolas Le Roux says commodity trading advisers (CTAs) are positioned to sharply increase their exposure to U.S. equity futures in the coming weeks, potentially quadrupling S&P 500 exposure by the end of April even if prices do not move higher. The bank's simulation shows divergent CTA behavior across regions and asset classes, includin…

Supreme Court to Rule on SEC’s Authority to Seek Disgorgement

Supreme Court to Rule on SEC’s Authority to Seek Disgorgement

The U.S. Supreme Court will hear arguments over the Securities and Exchange Commission’s ability to obtain disgorgement - the recovery of profits tied to unlawful conduct. The case centers on whether the SEC must demonstrate that victims suffered pecuniary harm before courts can order the return of ill-gotten gains, a question raised by the appeal …

Why the Eurozone's 2026 Earnings Surge May Be an Optical Illusion

Why the Eurozone's 2026 Earnings Surge May Be an Optical Illusion

The headline consensus projecting an 18% year-on-year rise in Eurozone earnings for 2026 conceals a much quieter underlying picture. IBES weighted estimates are skewed by an outsized recovery in the Consumer Discretionary sector, whose steep base effect inflates the aggregate figure. Median forecasts and sector-level detail point to more modest gai…